{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:17:27Z","timestamp":1787977047240,"version":"build-2784847793"},"reference-count":28,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.7565-26","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:12:01Z","timestamp":1787609521000},"source":"Crossref","is-referenced-by-count":0,"title":["Severe Multiorgan Failure Associated with Differentiation Syndrome in a High-risk Acute Promyelocytic Leukemia Patient with Concurrent Influenza A"],"prefix":"10.2169","author":[{"given":"Sunami","family":"Yoshimoto","sequence":"first","affiliation":[{"name":"Department of Postgraduate Training Center, Toyohashi Municipal Hospital, Japan"},{"name":"Department of Hematology and Oncology, Toyohashi Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Imoto","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Toyohashi Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Koketsu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Toyohashi Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyoshi","family":"Wakayama","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Toyohashi Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Ukai","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Toyohashi Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Toyohashi Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Kurahashi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Toyohashi Municipal Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Voso MT, Guarnera L, Lehmann S, et al. Acute promyelocytic leukemia: long-term outcomes from the HARMONY project. Blood 145: 234-243, 2025.","DOI":"10.1182\/blood.2024026186"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. De Botton S, Dombret H, Sanz M, et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. Blood 92: 2712-2718, 1998.","DOI":"10.1182\/blood.V92.8.2712.420k03_2712_2718"},{"key":"3","unstructured":"3. Tallman MS, Andersen JW, Schiffer CA, et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood 95: 90-95, 2000."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Stahl M, Tallman MS. Differentiation syndrome in acute promyelocytic leukaemia. Br J Haematol 187: 157-162, 2019.","DOI":"10.1111\/bjh.16151"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Montesinos P, Bergua JM, Vellenga E, et al. Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy. Blood 113: 775-783, 2009.","DOI":"10.1182\/blood-2008-07-168617"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Breccia M, Mazzarella L, Bagnardi V, et al. Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols. Blood 119: 49-54, 2012.","DOI":"10.1182\/blood-2011-07-369595"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Hegazy AN, Kr\u00f6nke J, Angermair S, et al. Anti-SARS-CoV-2 antibody-mediated cytokine release syndrome in a patient with acute promyelocytic leukemia. BMC Infect Dis 22: 537, 2022.","DOI":"10.1186\/s12879-022-07513-0"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Shim KG, Crain M, Augustin K, Oetjen KA. Management of acute promyelocytic leukemia in the setting of acute COVID-19 infection. Leuk Res Rep 18: 100353, 2022.","DOI":"10.1016\/j.lrr.2022.100353"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Sui J, Kelmenson D, Hu S, Cao L. Acute respiratory distress syndrome in a patient with acute promyelocytic leukemia: overlapping between differentiation syndrome and COVID-19. J Hematol 10: 217-220, 2021.","DOI":"10.14740\/jh904"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Sanz MA, Fenaux P, Tallman MS, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood 133: 1630-1643, 2019.","DOI":"10.1182\/blood-2019-01-894980"},{"key":"11","unstructured":"11. Japanese Society of Hematology. Guidelines for the Management of Hematologic Malignancies. Kanehara &amp; Co., Ltd., Tokyo, 2024."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Woods AC, Norsworthy KJ. Differentiation syndrome in acute leukemia: APL and beyond. Cancers (Basel) 15: 4767, 2023.","DOI":"10.3390\/cancers15194767"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Montesinos P, D\u00edaz-Mediavilla J, Deb\u00e9n G, et al. Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. Haematologica 94: 1242-1249, 2009.","DOI":"10.3324\/haematol.2009.007872"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. O\u2019Brien J, Tomlinson B, Patel MJ, et al. ATRA treatment in the emergency department is associated with reduced early mortality in acute promyelocytic leukemia-a real-world multicenter retrospective cohort analysis. Leuk Lymphoma 67: 1005-1013, 2026.","DOI":"10.1080\/10428194.2026.2623196"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Sanz MA, Montesinos P. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. Blood 123: 2777-2782, 2014.","DOI":"10.1182\/blood-2013-10-512640"},{"key":"16","unstructured":"16. Platzbecker U, Ad\u00e8s L, Montesinos P, et al. Arsenic trioxide and all-trans retinoic acid combination therapy for the treatment of high-risk acute promyelocytic leukemia: results from the APOLLO trial. J Clin Oncol 43: 3160-3169, 2025."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369: 111-121, 2013.","DOI":"10.1056\/NEJMoa1300874"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Lallemand-Breitenbach V, Jeanne M, Benhenda S. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4\/ubiquitin-mediated pathway. Nat Cell Biol 10: 547-555, 2008.","DOI":"10.1038\/ncb1717"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Takase K, Kimimura T, Kuriyama T, et al. Frontline ATRA-ATO therapy for acute promyelocytic leukemia in Japan: results from the prospective multicenter FBMTG-APL2017 trial. Cancer Sci 117: 1117-1123, 2026.","DOI":"10.1111\/cas.70328"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19: 3852-3860, 2001.","DOI":"10.1200\/JCO.2001.19.18.3852"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and\/or chemotherapy. Ann Oncol 17: 131-134, 2006.","DOI":"10.1093\/annonc\/mdj019"},{"key":"22","unstructured":"22. Marshall S, Imada Y, Kimura A, et al. Acute promyelocytic leukemia successfully treated with all-trans retinoic acid during hemodialysis for acute renal failure. Rinsho Ketsueki (Jpn J Clin Hematol) 64: 193-197, 2023."},{"key":"23","unstructured":"23. Dombret H, Sutton L, Duarte M, et al. Combined therapy with all-trans-retinoic acid and high-dose chemotherapy in patients with hyperleukocytic acute promyelocytic leukemia and severe visceral hemorrhage. Leukemia 6: 1237-1242, 1992."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Shen K, Yang C, Huang J, et al. The clinical characteristics and implications of acute kidney injury during induction therapy for acute promyelocytic leukemia. Front Pharmacol 16: 1540409, 2025.","DOI":"10.3389\/fphar.2025.1540409"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Firkin F, Roncolato F, Ho WK. Dose-adjusted arsenic trioxide for acute promyelocytic leukaemia in chronic renal failure. Eur J Haematol 95: 331-335, 2015.","DOI":"10.1111\/ejh.12502"},{"key":"26","unstructured":"26. Drugs.com [Internet]. Arsenic trioxide dosage and administration. [cited 2026 Mar 15]. Available from: https:\/\/www.drugs.com\/dosage\/arsenic-trioxide.html"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Emmons GS, Steingart RH, Stewart JA, Mertens WC. Relapsed acute promyelocytic leukemia in a hemodialysis-dependent patient treated with arsenic trioxide: a case report. J Med Case Rep 6: 355, 2012.","DOI":"10.1186\/1752-1947-6-355"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Hashimoto A, Tanaka Y, Shinzato I. Successful treatment of acute promyelocytic leukemia in a patient undergoing hemodialysis with arsenic trioxide. Clin Case Rep 9: e04300, 2021.","DOI":"10.1002\/ccr3.4300"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7565-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T03:31:42Z","timestamp":1787974302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7565-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":28,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7565-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"7565-26"}}